Premium
P1‐367: COMPARISON OF IOFLUPANE‐SPECT FINDINGS USING DATQUANT IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA AND DEMENTIA WITH LEWY BODIES
Author(s) -
Miyagawa Toji,
Przybelski Scott A.,
Maltais Daniela D.,
Min Hoon-Ki,
Jordan Len,
Lesnick Timothy G.,
Graff-Radford Jonathan,
Jones David T.,
Savica Rodolfo,
Drubach Daniel A.,
Knopman David S.,
Petersen Ronald C.,
Fields Julie A.,
Machulda Mary M.,
Forsberg Leah K.,
Allen Laura A.,
Nedelska Zuzana,
Parisi Joseph E.,
Murray Melissa E.,
Dickson Dennis W.,
Boeve Bradley F.,
Kantarci Kejal,
Lowe Val J.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.922
Subject(s) - putamen , dementia with lewy bodies , dementia , caudate nucleus , autopsy , medicine , pathology , alzheimer's disease , psychology , disease , nuclear medicine
measures (area under the curve, sensitivity, specificity, accuracy, positive and negative predictive values). Results: CDM_A was the best feature to distinguish between controls and all patients (highest AUC), and between controls and FTD groups. CDM_PAR was the best feature to distinguish between controls and PSPS, also between controls and CBS, and between FTD groups and PSPS. Conclusions: 1. From the set of cognitive measures, and whole brain MRI measurements of volume and cortical diffusion measurements, CDM_A achieved the highest classification power for differentiating tauopathies from healthy controls. 2. Novel cortical diffusion measurements (eg. CDM_PAR) could provide further differential markers to identify PSPS and CBS and to distinguish PSPS from FTD groups.